Intestinal Permeability in Irritable Bowel Syndrome Patients: Effects of NSAIDs

2009 ◽  
Vol 55 (3) ◽  
pp. 716-723 ◽  
Author(s):  
Angèle P. M. Kerckhoffs ◽  
Louis M. A. Akkermans ◽  
Martin B. M. de Smet ◽  
Marc G. H. Besselink ◽  
Falco Hietbrink ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Permeability ◽  
Irritable Bowel

scholarly journals Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Qiuke Hou ◽  
Yongquan Huang ◽  
Zhaoyang Zhu ◽  
Liu Liao ◽  
Xinlin Chen ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Permeability ◽  
Rat Model ◽  
Distal Colon ◽  
Notch Signalling ◽  
Signalling Pathways ◽  
Model Group ◽  
Related Factors ◽  
Defecation Frequency ◽  
Irritable Bowel

Abstract Background Tong-Xie-Yao-Fang (TXYF) has been shown to be effective in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients. However, the underlying mechanism remains to be clarified. The aim of this study was to investigate the efficacy and related mechanisms of TXYF in an IBS-D rat model. Methods The IBS-D rat model was established with 4% acetic acid and evaluated by haematoxylin-eosin (HE) staining. Then, IBS-D rats were divided into control, TXYF and rifaximin groups and treated intragastrically with normal saline, TXYF and rifaximin, respectively, for 14 days. The following indicators were measured before and after treatment: defecation frequency, faecal water content (FWC) and colorectal distension (CRD). Histopathological changes in the distal colon were observed after treatment. The expression of OCLN and ZO1 in the distal colon of IBS-D rats reflected the intestinal mucosal permeability, as measured by qRT-PCR, western blot, and enzyme-linked immunosorbent assays (ELISAs). The NF-κB and Notch signalling pathways and inflammation-related factors were investigated. Results After treatment with TXYF, the defecation frequency, FWC and CRD were significantly lower than those in the model group (P < 0.05). HE staining showed that colonic epithelial cells (CECs) in the IBS-D rats displayed significant oedema, impaired intestinal mucosal integrity and an increased influx of inflammatory cells. A significant reduction in granulocyte and CEC oedema was observed after the administration of TXYF and rifaximin compared to that of the model group and blank group (P < 0.05). TXYF significantly upregulated the expression of OCLN and ZO-1 and downregulated inflammation-related factors (IL-6, IL-1β, and TNF-α and the chemokine KC) in IBS-D rats compared to those in the model group rats (P < 0.05). In terms of the NF-κB and Notch signalling pathways, the expression of NICD, p-ERK, Hes-1 and p-P65 decreased significantly in the TXYF and rifaximin groups, while the expression of ATOH1 increased significantly compared to that in the model group (P < 0.05). Conclusion TXYF can effectively improve intestinal permeability and enhance intestinal mucosal barrier function, which may be related to inhibition of the inflammatory cascade and the NF-κB and Notch signalling pathways.

Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome

2012 ◽  
Vol 36 (11-12) ◽  
pp. 1009-1031 ◽  
Author(s):  
J. Matricon ◽  
M. Meleine ◽  
A. Gelot ◽  
T. Piche ◽  
M. Dapoigny ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Permeability ◽  
Immune Activation ◽  
Review Article ◽  
Irritable Bowel

Intestinal permeability is increased in children with irritable bowel syndrome: A case–control study

2017 ◽  
Vol 49 (4) ◽  
pp. e274-e275
Author(s):  
V. Giorgio ◽  
C. Russo ◽  
S. Filoni ◽  
F. Lecci ◽  
G. Giarrusso ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Permeability ◽  
Case Control Study ◽  
Case Control ◽  
Irritable Bowel ◽  
Control Study

scholarly journals Stool and urine trefoil factor 3 levels: associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome

2018 ◽  
Vol 9 (3) ◽  
pp. 345-355 ◽  
Author(s):  
M.M. Heitkemper ◽  
K.C. Cain ◽  
R.J. Shulman ◽  
R.L. Burr ◽  
C. Ko ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Microbial Diversity ◽  
Intestinal Permeability ◽  
Trefoil Factor ◽  
Contraception Use ◽  
Trefoil Factor 3 ◽  
Rome Iii ◽  
Irritable Bowel ◽  
Stool Microbiota ◽  
Relationship Of

Previously we showed that urine trefoil factor 3 (TFF3) levels were higher in females with irritable bowel syndrome (IBS) compared to non-IBS females. To assess if TFF3 is associated with symptoms and/or reflect alterations in gastrointestinal permeability and gut microbiota in an IBS population, we correlated stool and urine TFF3 levels with IBS symptoms, intestinal permeability, stool microbial diversity and relative abundance of predominant bacterial families and genera. We also tested the relationship of stool TFF3 to urine TFF3, and compared results based on hormone contraception use. Samples were obtained from 93 females meeting Rome III IBS criteria and completing 4-week symptom diaries. TFF3 levels were measured by ELISA. Permeability was assessed with the urine lactulose/mannitol (L/M) ratio. Stool microbiota was assessed using 16S rRNA. Stool TFF3, but not urine TFF3, was associated positively with diarrhoea and loose stool consistency. Higher stool TFF3 was also associated with lower L/M ratio and microbial diversity. Of the 20 most abundant bacterial families Mogibacteriaceae and Christensenellaceae were inversely related to stool TFF3, with only Christensenellaceae remaining significant after multiple comparison adjustment. There were no significant relationships between stool or urine TFF3 levels and other symptoms, nor between stool and urine levels. In premenopausal females, urine TFF3 levels were higher in those reporting hormone contraception. Collectively these results suggest that higher stool TFF3 levels are associated with IBS symptoms (loose/diarrhoeal stools), lower gut permeability, and altered stool bacteria composition (decreased diversity and decreased Christensenellaceae), which further suggests that TFF3 may be an important marker of host-bacteria interaction.

Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome

Gut ◽  
2018 ◽  
Vol 68 (6) ◽  
pp. 996-1002 ◽  
Author(s):  
QiQi Zhou ◽  
Meghan L Verne ◽  
Jeremy Z Fields ◽  
John J Lefante ◽  
Sarpreet Basra ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Adverse Events ◽  
Intestinal Permeability ◽  
Bowel Movement ◽  
Control Group ◽  
Enteric Infection ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
Bristol Stool Scale ◽  
Irritable Bowel

BackgroundMore effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection.MethodsEligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability.ResultsFifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8%) in the placebo group (a 14-fold difference). Glutamine also reduced all secondary endpoint means: IBS-SS score at 8 weeks (301 vs 181, p<0.0001), daily bowel movement frequency (5.4 vs 2.9±1.0, p<0.0001), Bristol Stool Scale (6.5 vs 3.9, p<0.0001) and intestinal permeability (0.11 vs 0.05; p<0.0001). ‘Intestinal hyperpermeability’ (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group. Adverse events and rates of study-drug discontinuation were low and similar in the two groups. No serious adverse events were observed.ConclusionsIn patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. Large randomised clinical trials (RCTs) should now be done to validate these findings, assess quality of life benefits and explore pharmacological mechanisms.Trial registration numberNCT1414244; Results.

Sign in / Sign up

Export Citation Format

Share Document